UK industry welcomes early access scheme, but says funding gap could limit interest
This article was originally published in Scrip
Executive Summary
The UK's long-awaited early access to medicines scheme (EAMS) is to be launched in April along with a new "promising innovative medicine" (PIM) designation that the government says will both give patients timely access to new drugs for serious diseases before they are approved and help companies secure investment for drugs under development at an earlier stage in the process.
You may also be interested in...
Progress Report: EAMS A Limited Success But Could Do Better
The UK's Early Access to Medicines Scheme (EAMS) has been operational for two years, along with a "promising innovative medicine" (PIM) designation, to give patients timely access to new drugs for serious diseases before they are approved. The system has now been independently reviewed and Scrip talks to those in the industry that have first-hand experience of the process.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.